100.10
price up icon4.10%   3.94
pre-market  プレマーケット:  101.00   0.90   +0.90%
loading
前日終値:
$96.16
開ける:
$97.3
24時間の取引高:
3.17M
Relative Volume:
2.24
時価総額:
$9.39B
収益:
$2.24B
当期純損益:
$385.90M
株価収益率:
26.84
EPS:
3.73
ネットキャッシュフロー:
$440.10M
1週間 パフォーマンス:
+5.06%
1か月 パフォーマンス:
-9.62%
6か月 パフォーマンス:
-15.42%
1年 パフォーマンス:
-24.73%
1日の値動き範囲:
Value
$97.30
$100.66
1週間の範囲:
Value
$87.70
$100.66
52週間の値動き範囲:
Value
$84.23
$157.98

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
名前
Neurocrine Biosciences Inc
Name
セクター
Healthcare (1155)
Name
電話
(858) 617-7600
Name
住所
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
職員
0
Name
Twitter
Name
次回の収益日
2024-10-30
Name
最新のSEC提出書
Name
NBIX's Discussions on Twitter

NBIX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - Specialty & Generic icon
NBIX
Neurocrine Biosciences Inc
100.10 9.39B 2.24B 385.90M 440.10M 3.73
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
146.76 65.46B 9.26B 2.49B 2.30B 5.47
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.65 46.11B 30.25B 1.37B 5.08B 0.4257
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.16 45.85B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
13.43 15.39B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
285.19 12.81B 2.76B 1.11B 898.10M 22.77

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-04-15 アップグレード Needham Hold → Buy
2025-04-14 アップグレード RBC Capital Mkts Sector Perform → Outperform
2025-02-11 開始されました Deutsche Bank Hold
2024-10-10 再開されました Raymond James Outperform
2024-08-29 アップグレード Piper Sandler Neutral → Overweight
2024-04-24 アップグレード Wells Fargo Equal Weight → Overweight
2023-12-13 再開されました Citigroup Neutral
2023-12-12 開始されました Deutsche Bank Buy
2023-10-24 再開されました Cantor Fitzgerald Overweight
2023-08-21 繰り返されました Mizuho Neutral
2023-07-24 アップグレード SVB Securities Market Perform → Outperform
2023-07-06 アップグレード BMO Capital Markets Underperform → Market Perform
2023-05-04 アップグレード Guggenheim Neutral → Buy
2023-03-30 アップグレード Canaccord Genuity Hold → Buy
2023-03-03 アップグレード Evercore ISI In-line → Outperform
2023-02-03 アップグレード Morgan Stanley Equal-Weight → Overweight
2022-11-14 ダウングレード Evercore ISI Outperform → In-line
2022-10-11 開始されました UBS Buy
2022-09-26 開始されました Wells Fargo Equal Weight
2022-06-06 再開されました Jefferies Buy
2022-03-03 ダウングレード Piper Sandler Overweight → Neutral
2022-02-25 アップグレード Goldman Neutral → Buy
2022-01-18 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2021-11-19 開始されました BMO Capital Markets Underperform
2021-11-17 アップグレード JP Morgan Neutral → Overweight
2021-10-14 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-09-23 再開されました Needham Hold
2021-08-06 ダウングレード Canaccord Genuity Buy → Hold
2021-05-18 再開されました Goldman Neutral
2021-05-06 アップグレード Barclays Equal Weight → Overweight
2021-02-02 開始されました Raymond James Outperform
2020-09-30 開始されました The Benchmark Company Hold
2020-08-04 ダウングレード JP Morgan Overweight → Neutral
2020-06-29 ダウングレード Goldman Buy → Neutral
2020-06-09 開始されました Wedbush Outperform
2020-03-06 開始されました Citigroup Buy
2020-02-27 開始されました Barclays Equal Weight
2020-02-24 開始されました William Blair Outperform
2020-02-06 開始されました Mizuho Neutral
2020-02-05 繰り返されました H.C. Wainwright Buy
2019-12-13 ダウングレード Credit Suisse Outperform → Neutral
2019-08-07 開始されました RBC Capital Mkts Outperform
2019-07-16 開始されました Oppenheimer Outperform
2019-06-05 開始されました Guggenheim Neutral
2019-05-21 開始されました Credit Suisse Outperform
2019-04-22 アップグレード JP Morgan Neutral → Overweight
2019-04-12 開始されました Evercore ISI Outperform
2019-02-06 繰り返されました BofA/Merrill Buy
2019-01-23 ダウングレード JP Morgan Overweight → Neutral
2018-12-13 開始されました Goldman Buy
2018-11-21 開始されました Canaccord Genuity Buy
すべてを表示

Neurocrine Biosciences Inc (NBIX) 最新ニュース

pulisher
Apr 16, 2025

Neurocrine Biosciences: Recent Selloff Has Created A Potential Buying Opportunity (NBIX) - Seeking Alpha

Apr 16, 2025
pulisher
Apr 16, 2025

Needham Upgrades Neurocrine Biosciences (LSE:0K6R) - Nasdaq

Apr 16, 2025
pulisher
Apr 15, 2025

Neurocrine Biosciences Stock Price, Quotes and Forecasts | NASDAQ:NBIX - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

Neurocrine Biosciences' Positive Crenessity Physician Survey Turns This Analyst Bullish - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

What 16 Analyst Ratings Have To Say About Neurocrine Biosciences - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

Needham Upgrades Neurocrine Biosciences (NBIX) - Nasdaq

Apr 15, 2025
pulisher
Apr 15, 2025

Needham Upgrades Neurocrine Biosciences to Buy From Hold, $138 Price Target - MarketScreener

Apr 15, 2025
pulisher
Apr 14, 2025

RBC Capital Upgrades Neurocrine Biosciences (LSE:0K6R) - Nasdaq

Apr 14, 2025
pulisher
Apr 14, 2025

RBC Capital lifts Neurocrine Bio. stock rating to Outperform By Investing.com - Investing.com Canada

Apr 14, 2025
pulisher
Apr 14, 2025

Neurocrine upgraded at RBC Capital Markets on recent selloff - MSN

Apr 14, 2025
pulisher
Apr 14, 2025

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results - Longview News-Journal

Apr 14, 2025
pulisher
Apr 14, 2025

RBC Capital Upgrades Neurocrine Biosciences (NBIX) - Nasdaq

Apr 14, 2025
pulisher
Apr 14, 2025

Neurocrine Biosciences Faces Relatively Less Exposure to FDA and Tariff-Related Concerns, RBC Says - MarketScreener

Apr 14, 2025
pulisher
Apr 14, 2025

Neurocrine stock upgraded at RBC Capital Markets (NBIX:NASDAQ) - Seeking Alpha

Apr 14, 2025
pulisher
Apr 14, 2025

RBC upgrades Neurocrine Biosciences on low tariff exposure for key drug - TradingView

Apr 14, 2025
pulisher
Apr 14, 2025

RBC Upgrades Neurocrine Biosciences to Outperform From Sector Perform, Trims Price Target to $137 From $138 - MarketScreener

Apr 14, 2025
pulisher
Apr 09, 2025

Sodium Channel Blockers Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.

Apr 09, 2025
pulisher
Apr 08, 2025

Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options - MSN

Apr 08, 2025
pulisher
Apr 08, 2025

Tourette Syndrome Treatment Market Generated Opportunities, - openPR.com

Apr 08, 2025
pulisher
Apr 05, 2025

Neurocrine Biosciences names Sanjay Keswani as chief medical officer - MSN

Apr 05, 2025
pulisher
Apr 05, 2025

Neurocrine Biosciences names new Chief Medical Officer By Investing.com - Investing.com Canada

Apr 05, 2025
pulisher
Apr 04, 2025

NBIXNeurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer - ADVFN

Apr 04, 2025
pulisher
Apr 04, 2025

Ex-Dyne team members reconvene at Crescent - biocentury.com

Apr 04, 2025
pulisher
Apr 04, 2025

Neurocrine Biosciences Appoints New Chief Medical Officer - MarketScreener

Apr 04, 2025
pulisher
Apr 04, 2025

UBS cuts Neurocrine Bio. stock target to $137, keeps Buy rating - Investing.com Canada

Apr 04, 2025
pulisher
Apr 04, 2025

Neurocrine Biosciences appoints new chief medical officer - The Pharma Letter

Apr 04, 2025
pulisher
Apr 04, 2025

Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medi - GuruFocus

Apr 04, 2025
pulisher
Apr 04, 2025

Neurocrine Biosciences names new Chief Medical Officer - Investing.com India

Apr 04, 2025
pulisher
Apr 04, 2025

Neurocrine Biosciences Appoints Sanjay Keswani as Chief Medical Officer - Contract Pharma

Apr 04, 2025
pulisher
Apr 04, 2025

Neurocrine Biosciences Appoints Dr. Sanjay Keswani As Chief Medical Officer - MarketScreener

Apr 04, 2025
pulisher
Apr 04, 2025

Neurocrine Biosciences (NBIX) Appoints Dr. Sanjay Keswani as Chief Medical Officer - StreetInsider

Apr 04, 2025
pulisher
Apr 04, 2025

UBS Lowers Price Target on Neurocrine Biosciences to $137 From $154, Keeps Buy Rating - MarketScreener

Apr 04, 2025
pulisher
Apr 04, 2025

Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer - PR Newswire

Apr 04, 2025
pulisher
Apr 04, 2025

Deutsche Bank Adjusts Neurocrine Biosciences Price Target to $135 From $138, Maintains Hold Rating - MarketScreener

Apr 04, 2025
pulisher
Apr 03, 2025

Neurocrine Biosci stock hits 52-week low at $105.17 By Investing.com - Investing.com South Africa

Apr 03, 2025
pulisher
Apr 03, 2025

Neurocrine Biosci stock hits 52-week low at $105.17 - Investing.com

Apr 03, 2025
pulisher
Apr 03, 2025

Cerebral Palsy Market Growth Projections 2024-2034: DelveInsight Analysis | Neurocrine Biosciences, Teva Pharma, Bundang CHA Hospital, Jazz Pharma - The Globe and Mail

Apr 03, 2025
pulisher
Apr 02, 2025

Mitsubishi UFJ Trust & Banking Corp Sells 4,578 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Apr 02, 2025
pulisher
Apr 02, 2025

Neurocrine Biosciences executive sells shares worth $266,024 - MSN

Apr 02, 2025
pulisher
Mar 31, 2025

Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia - PR Newswire

Mar 31, 2025
pulisher
Mar 31, 2025

New Data: INGREZZA Outperforms Competitors with Perfect Therapeutic Dose Rate - Stock Titan

Mar 31, 2025
pulisher
Mar 29, 2025

Supporting a Loved One Living with a Mental Health Condition and Tardive Dyskinesia - Main Street Media of Tennessee

Mar 29, 2025
pulisher
Mar 26, 2025

Neurocrine Biosciences: A Smart Biotech Bet With Blockbuster Potential - The Globe and Mail

Mar 26, 2025
pulisher
Mar 26, 2025

Deep Dive Into Neurocrine Biosciences Stock: Analyst Perspectives (14 Ratings) - Benzinga

Mar 26, 2025
pulisher
Mar 26, 2025

Ashland, Connectone Bancorp, Neurocrine Biosciences - TradingView

Mar 26, 2025
pulisher
Mar 25, 2025

Tardive Dyskinesia Treatment Market Expands with New Drug - openPR

Mar 25, 2025
pulisher
Mar 20, 2025

Neurocrine Biosciences debuts new data for effectiveness of Ingrezza - Yahoo

Mar 20, 2025
pulisher
Mar 20, 2025

Neurocrine touts further positive trial results for Ingrezza - The Pharma Letter

Mar 20, 2025
pulisher
Mar 20, 2025

Neurocrine Biosciences (NBIX) Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA Capsules - StreetInsider.com

Mar 20, 2025
pulisher
Mar 20, 2025

Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules - Longview News-Journal

Mar 20, 2025
pulisher
Mar 18, 2025

Endometriosis Pain Pipeline 2025: FDA Approvals and Clinical - openPR

Mar 18, 2025

Neurocrine Biosciences Inc (NBIX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$7.39
price down icon 1.20%
$100.52
price down icon 2.20%
$285.19
price up icon 0.13%
$27.20
price down icon 2.65%
$8.10
price down icon 1.70%
大文字化:     |  ボリューム (24 時間):